Inozyme Pharma Reports Interim Data From Phase 1 SEAPORT 1 Trial Of INZ-701; Treatment Well-Tolerated And Significantly Increases PPi Levels In ESKD Patients On Hemodialysis; Plans Registrational Trial In Calciphylaxis For 2025
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma has reported positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701, showing the treatment is well-tolerated and significantly increases PPi levels in ESKD patients on hemodialysis. The company plans a registrational trial in calciphylaxis for 2025.
October 24, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inozyme Pharma's INZ-701 has shown positive interim results in a Phase 1 trial, indicating the treatment is well-tolerated and effective in increasing PPi levels in ESKD patients. A registrational trial is planned for 2025.
The positive interim data from the Phase 1 trial of INZ-701 suggests potential efficacy and safety, which is likely to boost investor confidence and positively impact Inozyme Pharma's stock price. The announcement of a future registrational trial further supports long-term growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100